Updating, MultiCell Technologies (MCET.OB)
November 5th, 2010
No comments
MCET.OB and its majority owned subsidiary, Xenogenics acquired the Ideal™ BioStent assets Read more…
Categories: Product Aquisitions, Stem Cell Technology
